A Phase 1/2 interventional study of Intracerebral microinjections in Parkinson's Disease, sponsored by NeuroGeneration. Withdrawn. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by NeuroGeneration · Phase 1/2, Interventional, and Treatment
This is a prospective study to demonstrate the safety and efficacy of differentiated neurons-derived from adult CNS progenitors cells transplanted in selected patients with Parkinson's disease.
Parkinson's disease observed in the absence of:
Exclusion Criteria:
Biological: Intracerebral microinjections
Stereotactic delivery of cell suspension into basal ganglia structures
Motor UPDRS
UPDRS Motor scale
Time frame: 6 months
No study locations are listed for this record.
This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NeuroGeneration